Evolva Holding SA issued an announcement stating it had secured additional funding intended to support future growth. The notice was published as an EQS Group ad hoc release under the headline 'Evolva secures additional funding for future growth.' The release is dated 17‑May‑2021 and timed at 07:01 CET/CEST. The ad hoc announcement was made pursuant to Art. 53. The announcement does not specify the financing amount, instrument type, or any participating investors. It contains no operating metrics, past-round details, founding year, or location information. Evolva SA is a Swiss biotech that uses a genetic chemistry platform to develop small-molecule drugs. The company recently completed additional fundraising tied to a reverse merger that altered its corporate structure. Evolva added CHF16 million in additional Series B financing, bringing the round total to CHF44 million after an initial CHF28 million close in October. Backers named in the Series B include Wellington Partners, Aravis, Auriga Partners and Vinci Capital – Renaissance PME. The additional investment was part of Evolva’s reverse merger with Switzerland-listed Arpida Ltd. Separately, Evolva’s Indian subsidiary secured a CHF5 million funding commitment from Ventureast Trustee Company Pte Ltd. Evolva is a Basel-based Swiss biotech that develops clearly differentiated drug candidates and runs discovery partnerships that generate revenues. The company intends to progress its clinical compounds through phase II proof-of-concept trials over the next two to three years. To fund that work it will conduct a CHF 25m equity financing and says it has received positive feedback from existing and new investors. Evolva previously raised around $20m in venture capital from Novartis Venture, Aravis, Sunstone Capital and Dansk Innovationsinvestering. It currently employs 75 people, 30 of whom are located in Basel, and has operations in Denmark, the USA and India. The company has agreed to go public via a reverse merger with Arpida, which is listed on the Swiss stock exchange, and says the combined business will have promising growth prospects.

Total raised

$39M

Funding rounds

3

Latest round

Series B

Latest activity

Dec 2009